Description
FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing preclinical proof-of concept results showing antifibrotic efficacy and tolerability in relevant animal models. In addition, the proj…
Amendment chain · 6 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $1,995,126 at start, $2,282,176 after amendment #5 (+$287,050).
- #02021-02-01$1,995,126
- #12021-07-21$1,995,126
- #22021-12-01$1,995,126
- #32022-03-31$2,282,176+$287,050
- #42022-09-20$2,282,176
- #52022-12-08$2,282,176
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2021-02-01(start date) | $1,995,126 | — | FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing pr… |
| #1 amendment | 2021-07-21 | $1,995,126 | +$0 | FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing pr… |
| #2 amendment | 2021-12-01 | $1,995,126 | +$0 | FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing pr… |
| #3 amendment | 2022-03-31 | $2,282,176 | +$287,050 | FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing pr… |
| #4 amendment | 2022-09-20 | $2,282,176 | +$0 | FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing pr… |
| #5 amendment | 2022-12-08 | $2,282,176 | +$0 | FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing pr… |
Related records · 5
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q4-966019 · retrieved 2026-11-15.